Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN) in First-line Treatment mCRC Patients
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2161339
下载链接
链接失效反馈官方服务：
资源简介：
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin in combination with FOLFOX (any) or FOLFIRI chemotherapy.
FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
创建时间：
2014-10-15
